Genzyme Corp.
3Q Revenues: $960 million (+19%)
3Q Earnings: $159 million (up from $16 million in 3Q06)
YTD Revenues: $2.8 billion (+19%)
YTD Earnings: $401 million (+60%)
Comments: Myzozyme sales rose 162% to $54 million in 3Q07, and the company is hoping to gain approval for a new large-scale manufacturing process in the U.S. Fabrazyme sales grew 12% to $105 million and Cerezyme was up 13% to $286 million. Genzyme expanded its line this quarter by acquiring several new products and gaining new labels for others. During the quarter, the company also took a $12 million writeoff for four batches of its transplantation product Thymoglobulin which "did not meet the company's specifications."
Magazine
